Veterans Aging Cohort Study (VACS) 2.0 Index

ورودی‌های بالینی بیمار

حداقل ۱۸ — حداکثر ۱۰۰ • واحد: years

حداقل ۰ — حداکثر ۲۰۰۰ • واحد: cells/μL

حداقل ۰ — حداکثر ۷ • واحد: log10 copies/mL

حداقل ۵ — حداکثر ۲۰ • واحد: g/dL

حداقل ۱۰ — حداکثر ۱۰۰۰ • واحد: ×10³/μL

حداقل ۱۰ — حداکثر ۵۰۰ • واحد: U/L

حداقل ۱۰ — حداکثر ۵۰۰ • واحد: U/L

حداقل ۰.۵ — حداکثر ۱۰ • واحد: mg/dL

حداقل ۱ — حداکثر ۶ • واحد: g/dL

حداقل ۱ — حداکثر ۵۰ • واحد: ×10³/μL

حداقل ۱۰ — حداکثر ۵۰ • واحد: kg/m²

پنل نتیجه و تصمیم بالینی
در انتظار ورودی‌ها
vacs 2 0 score
—points
آماده برای ارزیابی

پارامترهای بالینی بیمار را در فرم روبرو وارد کنید و روی «محاسبه» کلیک نمایید تا نمره، طبقه خطر و اقدامات فوری نمایش داده شوند.

طبقات خطر و بازه‌های امتیاز:
  • Low Risk0–25
  • Moderate Risk26–50
  • High Risk51–75
  • Very High Risk76–164
Direct Clinical Answer

The Veterans Aging Cohort Study (VACS) 2.0 Index calculates predicting invasive bacterial infection probability and quantifying systemic host response to sepsis. Key inputs include age. Scores guide administering empiric broad-spectrum antimicrobial regimens, infectious source control, and isolation protocols. This standardized assessment improves clinical decision safety and bedside patient management.

Clinical Guidelines & Evidence

Estimates 5-year all-cause mortality risk in patients with HIV using age, HIV-specific biomarkers, and general health indicators. An improved version of the original VACS Index with enhanced discrimination.

Clinical Indication

The Veterans Aging Cohort Study (VACS) 2.0 Index is indicated for bedside clinical practice to support Estimates 5-year all-cause mortality risk in patients with HIV using age, HIV-specific biomarkers, and general health indicators. An improved version of the original VACS Index with enhanced discrimination.. It assists healthcare providers in standardizing clinical assessment and therapeutic decision-making.

Target Population

Target population comprises Patients presenting with suspected sepsis, meningitis, pneumonia, COVID-19, opportunistic infections, or fever of unknown origin. Clinical application is indicated across Infectious disease services, septic shock bays, febrile illness clinics, and isolation units.

Limitations & Contraindications

Timely administration of empiric antibiotic therapy in suspected septic shock must never be delayed for score tabulation.

Clinical Pearls & Action Plan

Blood and site-specific microbiological cultures should be secured prior to administering broad-spectrum antimicrobials.

Formula & Variables:

VACS 2.0 = f(Age, CD4, HIV RNA, Hemoglobin, FIB-4, eGFR, Albumin, WBC, BMI, HCV) where FIB-4 = (Age × AST) / (Platelets × √ALT) and eGFR calculated using CKD-EPI equation

Input Parameters

NameTypeRequiredDescription
ageintegerYesPatient age in years(years)
sexstringYesPatient sex for eGFR calculation
racestringYesPatient race for eGFR calculation
cd4_countintegerYesCD4 T-cell count (cells/μL)(cells/μL)
hiv_rna_logfloatYesHIV-1 RNA viral load (log10 copies/mL)(log10 copies/mL)
hemoglobinfloatYesHemoglobin level (g/dL)(g/dL)
plateletsintegerYesPlatelet count (×10³/μL)(×10³/μL)
astintegerYesAspartate aminotransferase (U/L)(U/L)
altintegerYesAlanine aminotransferase (U/L)(U/L)
creatininefloatYesSerum creatinine (mg/dL)(mg/dL)
albuminfloatYesSerum albumin (g/dL)(g/dL)
wbc_countfloatYesWhite blood cell count (×10³/μL)(×10³/μL)
bmifloatYesBody mass index (kg/m²)(kg/m²)
hepatitis_cstringYesHepatitis C virus co-infection status

Score Interpretation & Guidance

RangeStageDescription
0–25Low RiskLow 5-year mortality risk
26–50Moderate RiskModerate 5-year mortality risk
51–75High RiskHigh 5-year mortality risk
76–164Very High RiskVery high 5-year mortality risk

Evidence-Based References (EBM)

  • Justice AC, Lasky E, McGinnis KA, et al. Medical disease and alcohol use among veterans with human immunodeficiency virus infection: A comparison of disease measurement strategies. Med Care. 2006;44(8 Suppl 2):S52-60.
  • Justice AC, McGinnis KA, Skanderson M, et al. Towards a combined prognostic index for survival in HIV infection: the role of 'non-HIV' biomarkers. HIV Med. 2010;11(2):143-51.
  • Tate JP, Justice AC, Hughes MD, et al. An internationally generalizable risk index for mortality after one year of antiretroviral therapy. AIDS. 2013;27(4):563-72.
  • Justice AC, Erlandson KM, Hunt PW, et al. Development and validation of a prognostic index for 1-year mortality in HIV-infected adults. Med Care. 2013;51(12):1054-64.
  • Rodriguez-Barradas MC, Tate JP, Justice AC, et al. Albumin, white blood cell count, and body mass index improve discrimination of mortality in HIV-positive individuals. AIDS. 2019;33(6):903-912.

Related calculators